Capricor Therapeutics, Inc.

Capricor Therapeutics is a small-cap biotech whose lead asset, deramiocel (CAP-1002), is up for an FDA Cellular, Tissue and Gene Therapies Advisory Committee meeting on July 29 and a PDUFA target action date of August 22 — in Duchenne muscular dystrophy, one of the highest-value rare-disease indications.

• The setup is textbook squeeze-plus-catalyst: institutional buying continues while retail short interest stays elevated, and the sentiment is explicitly framing this as a "Sarepta-style squeeze" pattern into the AdCom — the specific mechanics that produce violent covering when a positive vote materializes.
• The mechanics are entirely optionality math: TTM revenue is zero, operating margin is essentially undefined, and a -107% FCF yield means the equity is a pre-revenue biotech burning cash into a binary event window — no operating base to fall back on.
• The trial-integrity concern is the specific new bear datapoint: a recent "may have been inadvertently unblinded" disclosure fuels the argument that the FDA panel might question the pivotal-trial data — that's a real risk, not just sentiment.
• The tape is showing dip-buying mid-catalyst: shares are 23% below the 50-day but essentially flat versus the 200-day at the 50th percentile of the range, with volume 67% above trend — that's exactly the shape of accumulation into a defined catalyst window on real flow.

The July 29 AdCom and the August 22 PDUFA are the entire trade. A positive AdCom recommendation with a clean panel discussion and CAPR moves violently higher on the covering; a negative panel focused on the unblinding disclosure or a CRL and the equity gives back the +126% year-over-year run in a single session. Size to loss — the Aug 11 corporate update is a data point but the real settlement is the FDA process.